Even After Growth, ResMed Has Plenty of Room to Run
As a nation, we're getting older -- and for many of us, weight gain comes with age. These trends can help explain the impressive growth of ResMed (NYSE: RMD), a manufacturer of continuous positive airway pressure (CPAP) equipment used to treat sleep apnea.
Research by the National Center on Sleep Disorders shows that sleep-disordered breathing affects nearly 15% of the population, and more than two decades of research by the Wisconsin Sleep Cohort Study produced the conclusion that incidences of sleep apnea will likely rise as our population ages and because of the obesity epidemic.
ResMed has seen a 60% jump in its stock price over the past 52 weeks and has enjoyed adjusted EPS growth of 9% over the past five fiscal years. While other medical supply companies are seeing strong headwinds because of the COVID-19 pandemic, ResMed's shares have continued to climb after a momentary dip in late March. Here are a few reasons why.
Source Fool.com
